Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
Saved in:
| Title: | Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. |
|---|---|
| Authors: | Rice A; ImmunityBio, Inc., Culver City, CA, United States., Verma M; ImmunityBio, Inc., Culver City, CA, United States., Voigt E; Access to Advanced Health Institute (AAHI), Seattle, WA, United States., Battisti P; Access to Advanced Health Institute (AAHI), Seattle, WA, United States., Beaver S; Access to Advanced Health Institute (AAHI), Seattle, WA, United States., Reed S; Access to Advanced Health Institute (AAHI), Seattle, WA, United States., Dinkins K; ImmunityBio, Inc., Culver City, CA, United States., Mody S; ImmunityBio, Inc., Culver City, CA, United States., Zakin L; ImmunityBio, Inc., Culver City, CA, United States., Tanaka S; ImmunityBio, Inc., Culver City, CA, United States., Morimoto B; ImmunityBio, Inc., Culver City, CA, United States., Olson CA; ImmunityBio, Inc., Culver City, CA, United States., Gabitzsch E; ImmunityBio, Inc., Culver City, CA, United States., Safrit JT; ImmunityBio, Inc., Culver City, CA, United States., Spilman P; ImmunityBio, Inc., Culver City, CA, United States., Casper C; Access to Advanced Health Institute (AAHI), Seattle, WA, United States.; Departments of Medicine and Global Health, University of Washington, Seattle, WA, United States., Soon-Shiong P; ImmunityBio, Inc., Culver City, CA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2022 Jul 15; Vol. 13, pp. 910136. Date of Electronic Publication: 2022 Jul 15 (Print Publication: 2022). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35911728 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rice+A%22">Rice A</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Verma+M%22">Verma M</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Voigt+E%22">Voigt E</searchLink>; Access to Advanced Health Institute (AAHI), Seattle, WA, United States.<br /><searchLink fieldCode="AU" term="%22Battisti+P%22">Battisti P</searchLink>; Access to Advanced Health Institute (AAHI), Seattle, WA, United States.<br /><searchLink fieldCode="AU" term="%22Beaver+S%22">Beaver S</searchLink>; Access to Advanced Health Institute (AAHI), Seattle, WA, United States.<br /><searchLink fieldCode="AU" term="%22Reed+S%22">Reed S</searchLink>; Access to Advanced Health Institute (AAHI), Seattle, WA, United States.<br /><searchLink fieldCode="AU" term="%22Dinkins+K%22">Dinkins K</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Mody+S%22">Mody S</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Zakin+L%22">Zakin L</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Tanaka+S%22">Tanaka S</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Morimoto+B%22">Morimoto B</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Olson+CA%22">Olson CA</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Gabitzsch+E%22">Gabitzsch E</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Safrit+JT%22">Safrit JT</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Spilman+P%22">Spilman P</searchLink>; ImmunityBio, Inc., Culver City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Casper+C%22">Casper C</searchLink>; Access to Advanced Health Institute (AAHI), Seattle, WA, United States.; Departments of Medicine and Global Health, University of Washington, Seattle, WA, United States.<br /><searchLink fieldCode="AU" term="%22Soon-Shiong+P%22">Soon-Shiong P</searchLink>; ImmunityBio, Inc., Culver City, CA, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2022 Jul 15; Vol. 13, pp. 910136. <i>Date of Electronic Publication: </i>2022 Jul 15 (<i>Print Publication: </i>2022). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35911728 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fimmu.2022.910136 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 910136 Titles: – TitleFull: Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rice A – PersonEntity: Name: NameFull: Verma M – PersonEntity: Name: NameFull: Voigt E – PersonEntity: Name: NameFull: Battisti P – PersonEntity: Name: NameFull: Beaver S – PersonEntity: Name: NameFull: Reed S – PersonEntity: Name: NameFull: Dinkins K – PersonEntity: Name: NameFull: Mody S – PersonEntity: Name: NameFull: Zakin L – PersonEntity: Name: NameFull: Tanaka S – PersonEntity: Name: NameFull: Morimoto B – PersonEntity: Name: NameFull: Olson CA – PersonEntity: Name: NameFull: Gabitzsch E – PersonEntity: Name: NameFull: Safrit JT – PersonEntity: Name: NameFull: Spilman P – PersonEntity: Name: NameFull: Casper C – PersonEntity: Name: NameFull: Soon-Shiong P IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 07 Text: 2022 Jul 15 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1664-3224 Numbering: – Type: volume Value: 13 Titles: – TitleFull: Frontiers in immunology Type: main |
| ResultId | 1 |
